Previous close | 0.1800 |
Open | 0.2000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 95.00 |
Expiry date | 2022-07-15 |
Day's range | 0.1800 - 0.2000 |
Contract range | N/A |
Volume | |
Open interest | N/A |
SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets primary and key secondary endpoints.
Dividend stocks can be a great place to start looking. A couple of Dividend Kings that have been doing particularly well this year are AbbVie (NYSE: ABBV) and Altria Group (NYSE: MO). AbbVie is a top healthcare stock that yields 3.7% annually, which is more than double the S&P 500 average of less than 1.4%.
AbbVie (NYSE: ABBV) will participate in the Bernstein 38th Annual Strategic Decisions Conference on Wednesday, June 1, 2022. Richard A. Gonzalez, chairman and chief executive officer, will present at 10:00 a.m. Central Time.